Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 5
2005 3
2006 2
2007 4
2008 1
2010 3
2011 2
2012 1
2014 5
2015 4
2016 5
2017 3
2018 3
2019 4
2020 5
2021 18
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
Wang X, Feng M, Xiao T, Guo B, Liu D, Liu C, Pei J, Liu Q, Xiao Y, Rosin-Arbesfeld R, Shi Y, Zhou Y, Yang M, Feng YX, Jiang Y, Shao Z, Yu K, Zhu D. Wang X, et al. Oncogene. 2021 Apr;40(16):2982-2997. doi: 10.1038/s41388-021-01756-y. Epub 2021 Mar 25. Oncogene. 2021. PMID: 33767438
Here we demonstrate that the expression of BCL9 and BCL9L is directly correlated with malignancy in TNBC patient tumors and that BCL9 and BCL9L promote tumor cell growth, cell migration and metastasis in TNBC models. Mechanistically, we found that BCL9/BCL9L …
Here we demonstrate that the expression of BCL9 and BCL9L is directly correlated with malignancy in TNBC patient tumors and that BCL9 …
NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer progression.
Wang G, Zhang M, Zhang Y, Xie Y, Zou J, Zhong J, Zheng Z, Zhou X, Zheng Y, Chen B, Liu C. Wang G, et al. Clin Transl Med. 2022 May;12(5):e738. doi: 10.1002/ctm2.738. Clin Transl Med. 2022. PMID: 35522942 Free PMC article.
NAT10 was responsible for mRNA ac4C modification in BLCA cells, including BCL9L, SOX4 and AKT1. Deficient NAT10 in both xenograft and transgenic mouse models of bladder cancer reduced the tumor burden. ...NAT10 is responsible for ac4C modification of target transcripts, in …
NAT10 was responsible for mRNA ac4C modification in BLCA cells, including BCL9L, SOX4 and AKT1. Deficient NAT10 in both xenograft and …
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Giannakis M, et al. Cell Rep. 2016 Apr 26;15(4):857-865. doi: 10.1016/j.celrep.2016.03.075. Epub 2016 Apr 14. Cell Rep. 2016. PMID: 27149842 Free PMC article.
We performed whole-exome sequencing of 619 incident colorectal cancers (CRCs) and integrated the results with tumor immunity, pathology, and survival data. We identified recurrently mutated genes in CRC, such as BCL9L, RBM10, CTCF, and KLF5, that were not previously apprec …
We performed whole-exome sequencing of 619 incident colorectal cancers (CRCs) and integrated the results with tumor immunity, pathology, and …
BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer.
López-García C, Sansregret L, Domingo E, McGranahan N, Hobor S, Birkbak NJ, Horswell S, Grönroos E, Favero F, Rowan AJ, Matthews N, Begum S, Phillimore B, Burrell R, Oukrif D, Spencer-Dene B, Kovac M, Stamp G, Stewart A, Danielsen H, Novelli M, Tomlinson I, Swanton C. López-García C, et al. Cancer Cell. 2017 Jan 9;31(1):79-93. doi: 10.1016/j.ccell.2016.11.001. Cancer Cell. 2017. PMID: 28073006 Free PMC article.
Through genomic analysis of colorectal cancers and cell lines, we find frequent loss of heterozygosity and mutations in BCL9L in aneuploid tumors. BCL9L deficiency promoted tolerance of chromosome missegregation events, propagation of aneuploidy, and genetic heterog …
Through genomic analysis of colorectal cancers and cell lines, we find frequent loss of heterozygosity and mutations in BCL9L in aneu …
Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M. Katoh M. Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. Int J Mol Med. 2018. PMID: 29786110 Free PMC article. Review.
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadherin/CDH5 and alpha-catenins), transmembrane-type mucins (MUC1/CD227 and MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 and NHERF1/EBP5 …
beta-catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E-cadherin/CDH1, N-cadherin/CDH2, VE-cadher …
The interactions of Bcl9/Bcl9L with beta-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
Vafaizadeh V, Buechel D, Rubinstein N, Kalathur RKR, Bazzani L, Saxena M, Valenta T, Hausmann G, Cantù C, Basler K, Christofori G. Vafaizadeh V, et al. Oncogene. 2021 Oct;40(43):6195-6209. doi: 10.1038/s41388-021-02016-9. Epub 2021 Sep 20. Oncogene. 2021. PMID: 34545187 Free PMC article.
Conditional knockout of both Bcl9 and Bcl9L resulted into tumor cell death. In contrast, disrupting the interaction of Bcl9/Bcl9L with beta-catenin, either by deletion of their HD2 domains or by a point mutation in the N-terminal domain of beta-catenin (D164A), dimi …
Conditional knockout of both Bcl9 and Bcl9L resulted into tumor cell death. In contrast, disrupting the interaction of Bcl9/Bcl9L …
Wnt/beta-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer Cells.
Kotolloshi R, Gajda M, Grimm MO, Steinbach D. Kotolloshi R, et al. Int J Mol Sci. 2022 May 10;23(10):5319. doi: 10.3390/ijms23105319. Int J Mol Sci. 2022. PMID: 35628130 Free PMC article.
We assessed the influence of UTRs mutations on BCL9L, and the role of BCL9L and Wnt/beta-catenin signalling in BC cells. ...BCL9L is predominantly increased in dysplastic urothelial cells and muscle-invasive BC. ...
We assessed the influence of UTRs mutations on BCL9L, and the role of BCL9L and Wnt/beta-catenin signalling in BC cells. ... …
BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.
Hallas C, Phillipp J, Domanowsky L, Kah B, Tiemann K. Hallas C, et al. BMC Cancer. 2016 Aug 18;16:648. doi: 10.1186/s12885-016-2707-1. BMC Cancer. 2016. PMID: 27539223 Free PMC article.

RESULTS: The results demonstrated a differential RNA-expression of BCL9L with a lack of expression in SPN (p < 0.001), RNA levels similar to normal tissue in IPMN and increased expression in PDAC (p < 0.04). ...In contrast, high expression of the gene was detected in

…

RESULTS: The results demonstrated a differential RNA-expression of BCL9L with a lack of expression in SPN (p < 0.001), RNA levels

…
Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N, Sandbothe M, Schröder AK, Stalke A, Eilers M, Schäffer V, Schlegelberger B, Illig T, Vajen B, Skawran B. Huge N, et al. Hepatol Int. 2020 May;14(3):373-384. doi: 10.1007/s12072-019-09977-w. Epub 2019 Aug 22. Hepatol Int. 2020. PMID: 31440992 Free PMC article.
RESULTS: Knockdown of BCL9L, but not of BCL9, reduced Wnt signaling activity. Knockdown of BCL9 and/or BCL9L reduced cell viability and increased apoptosis of Wnt-inactive HCC cells, but had no effect in Wnt-active cells. ...For BCL9L, higher expression was o …
RESULTS: Knockdown of BCL9L, but not of BCL9, reduced Wnt signaling activity. Knockdown of BCL9 and/or BCL9L reduced cell viab …
78 results